A BILL 
To prohibit brand name drug manufacturers from compen-
sating generic drug manufacturers to delay the entry 
of a generic drug into the market, and to prohibit bio-
logical product manufacturers from compensating bio-
similar and interchangeable product manufacturers to 
delay entry of biosimilar and interchangeable products, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
23:50 Jan 28, 2021
H153
2 
•HR 153 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Protecting Consumer 
2
Access to Generic Drugs Act of 2021’’. 
3
SEC. 2. UNLAWFUL AGREEMENTS. 
4
(a) AGREEMENTS PROHIBITED.—Subject to sub-
5
sections (b) and (c), it shall be unlawful for an NDA or 
6
BLA holder and a subsequent filer (or for two subsequent 
7
filers) to enter into, or carry out, an agreement resolving 
8
or settling a covered patent infringement claim on a final 
9
or interim basis if under such agreement— 
10
(1) a subsequent filer directly or indirectly re-
11
ceives from such holder (or in the case of such an 
12
agreement between two subsequent filers, the other 
13
subsequent filer) anything of value, including a li-
14
cense; and 
15
(2) the subsequent filer agrees to limit or fore-
16
go research on, or development, manufacturing, 
17
marketing, or sales, for any period of time, of the 
18
covered product that is the subject of the application 
19
described in subparagraph (A) or (B) of subsection 
20
(g)(8). 
21
(b) EXCLUSION.—It shall not be unlawful under sub-
22
section (a) if a party to an agreement described in such 
23
subsection demonstrates by clear and convincing evidence 
24
that the value described in subsection (a)(1) is compensa-
25
23:50 Jan 28, 2021
H153
3 
•HR 153 IH
tion solely for other goods or services that the subsequent 
1
filer has promised to provide. 
2
(c) LIMITATION.—Nothing in this section shall pro-
3
hibit an agreement resolving or settling a covered patent 
4
infringement claim in which the consideration granted by 
5
the NDA or BLA holder to the subsequent filer (or from 
6
one subsequent filer to another) as part of the resolution 
7
or settlement includes only one or more of the following: 
8
(1) The right to market the covered product 
9
that is the subject of the application described in 
10
subparagraph (A) or (B) of subsection (g)(8) in the 
11
United States before the expiration of— 
12
(A) any patent that is the basis of the cov-
13
ered patent infringement claim; or 
14
(B) any patent right or other statutory ex-
15
clusivity that would prevent the marketing of 
16
such covered product. 
17
(2) A payment for reasonable litigation ex-
18
penses not to exceed $7,500,000 in the aggregate. 
19
(3) A covenant not to sue on any claim that 
20
such covered product infringes a patent. 
21
(d) ENFORCEMENT BY FEDERAL TRADE COMMIS-
22
SION.— 
23
23:50 Jan 28, 2021
H153
4 
•HR 153 IH
(1) GENERAL APPLICATION.—The requirements 
1
of this section apply, according to their terms, to an 
2
NDA or BLA holder or subsequent filer that is— 
3
(A) a person, partnership, or corporation 
4
over which the Commission has authority pur-
5
suant to section 5(a)(2) of the Federal Trade 
6
Commission Act (15 U.S.C. 45(a)(2)); or 
7
(B) a person, partnership, or corporation 
8
over which the Commission would have author-
9
ity pursuant to such section but for the fact 
10
that such person, partnership, or corporation is 
11
not organized to carry on business for its own 
12
profit or that of its members. 
13
(2) UNFAIR OR DECEPTIVE ACTS OR PRACTICES 
14
ENFORCEMENT AUTHORITY.— 
15
(A) IN GENERAL.—A violation of this sec-
16
tion shall be treated as an unfair or deceptive 
17
act or practice in violation of section 5(a)(1) of 
18
the Federal Trade Commission Act (15 U.S.C. 
19
45(a)(1)). 
20
(B) POWERS OF COMMISSION.—Except as 
21
provided in subparagraph (C) and paragraphs 
22
(1)(B) and (3)— 
23
(i) the Commission shall enforce this 
24
section in the same manner, by the same 
25
23:50 Jan 28, 2021
H153
5 
•HR 153 IH
means, and with the same jurisdiction, 
1
powers, and duties as though all applicable 
2
terms and provisions of the Federal Trade 
3
Commission Act (15 U.S.C. 41 et seq.) 
4
were incorporated into and made a part of 
5
this section; and 
6
(ii) any NDA or BLA holder or subse-
7
quent filer that violates this section shall 
8
be subject to the penalties and entitled to 
9
the privileges and immunities provided in 
10
the Federal Trade Commission Act. 
11
(C) JUDICIAL REVIEW.—In the case of a 
12
cease and desist order issued by the Commis-
13
sion under section 5 of the Federal Trade Com-
14
mission Act (15 U.S.C. 45) for violation of this 
15
section, a party to such order may obtain judi-
16
cial review of such order as provided in such 
17
section 5, except that— 
18
(i) such review may only be obtained 
19
in— 
20
(I) the United States Court of 
21
Appeals for the District of Columbia 
22
Circuit; 
23
(II) the United States Court of 
24
Appeals for the circuit in which the 
25
23:50 Jan 28, 2021
H153
6 
•HR 153 IH
ultimate parent entity, as defined in 
1
section 801.1(a)(3) of title 16, Code 
2
of Federal Regulations, or any suc-
3
cessor thereto, of the NDA or BLA 
4
holder (if any such holder is a party 
5
to such order) is incorporated as of 
6
the date that the application described 
7
in subparagraph (A) or (B) of sub-
8
section (g)(8) or an approved applica-
9
tion that is deemed to be a license for 
10
a biological product under section 
11
351(k) of the Public Health Service 
12
Act (42 U.S.C. 262(k)) pursuant to 
13
section 7002(e)(4) of the Biologics 
14
Price Competition and Innovation Act 
15
of 2009 (Public Law 111–148; 124 
16
Stat. 817) is submitted to the Com-
17
missioner of Food and Drugs; or 
18
(III) the United States Court of 
19
Appeals for the circuit in which the 
20
ultimate parent entity, as so defined, 
21
of any subsequent filer that is a party 
22
to such order is incorporated as of the 
23
date that the application described in 
24
subparagraph (A) or (B) of subsection 
25
23:50 Jan 28, 2021
H153
7 
•HR 153 IH
(g)(8) is submitted to the Commis-
1
sioner of Food and Drugs; and 
2
(ii) the petition for review shall be 
3
filed in the court not later than 30 days 
4
after such order is served on the party 
5
seeking review. 
6
(3) ADDITIONAL ENFORCEMENT AUTHORITY.— 
7
(A) CIVIL
PENALTY.—The Commission 
8
may commence a civil action to recover a civil 
9
penalty in a district court of the United States 
10
against any NDA or BLA holder or subsequent 
11
filer that violates this section. 
12
(B) SPECIAL
RULE
FOR
RECOVERY
OF 
13
PENALTY
IF
CEASE
AND
DESIST
ORDER 
14
ISSUED.— 
15
(i) IN GENERAL.—If the Commission 
16
has issued a cease and desist order in a 
17
proceeding under section 5 of the Federal 
18
Trade Commission Act (15 U.S.C. 45) for 
19
violation of this section— 
20
(I) the Commission may com-
21
mence a civil action under subpara-
22
graph (A) to recover a civil penalty 
23
against any party to such order at 
24
any time before the expiration of the 
25
23:50 Jan 28, 2021
H153
8 
•HR 153 IH
1-year period beginning on the date 
1
on which such order becomes final 
2
under section 5(g) of such Act (15 
3
U.S.C. 45(g)); and 
4
(II) in such civil action, the find-
5
ings of the Commission as to the ma-
6
terial facts in such proceeding shall be 
7
conclusive, unless— 
8
(aa) the terms of such order 
9
expressly provide that the Com-
10
mission’s findings shall not be 
11
conclusive; or 
12
(bb) such order became final 
13
by reason of section 5(g)(1) of 
14
such Act (15 U.S.C. 45(g)(1)), in 
15
which case such findings shall be 
16
conclusive if supported by evi-
17
dence. 
18
(ii) RELATIONSHIP TO PENALTY FOR 
19
VIOLATION
OF
AN
ORDER.—The penalty 
20
provided in clause (i) for violation of this 
21
section is separate from and in addition to 
22
any penalty that may be incurred for viola-
23
tion of an order of the Commission under 
24
23:50 Jan 28, 2021
H153
9 
•HR 153 IH
section 5(l) of the Federal Trade Commis-
1
sion Act (15 U.S.C. 45(l)). 
2
(C) AMOUNT OF PENALTY.— 
3
(i) IN GENERAL.—The amount of a 
4
civil penalty imposed in a civil action under 
5
subparagraph (A) on a party to an agree-
6
ment described in subsection (a) shall be 
7
sufficient to deter violations of this section, 
8
but in no event greater than— 
9
(I) if such party is the NDA or 
10
BLA holder (or, in the case of an 
11
agreement between two subsequent fil-
12
ers, the subsequent filer who gave the 
13
value described in subsection (a)(1)), 
14
the greater of— 
15
(aa) 3 times the value re-
16
ceived by such NDA or BLA 
17
holder (or by such subsequent 
18
filer) that is reasonably attrib-
19
utable to the violation of this sec-
20
tion; or 
21
(bb) 3 times the value given 
22
to the subsequent filer (or to the 
23
other subsequent filer) reason-
24
23:50 Jan 28, 2021
H153
10 
•HR 153 IH
ably attributable to the violation 
1
of this section; and 
2
(II) if such party is the subse-
3
quent filer (or, in the case of an 
4
agreement between two subsequent fil-
5
ers, the subsequent filer who received 
6
the value described in subsection 
7
(a)(1)), 3 times the value received by 
8
such subsequent filer that is reason-
9
ably attributable to the violation of 
10
this section. 
11
(ii) FACTORS FOR CONSIDERATION.— 
12
In determining such amount, the court 
13
shall take into account— 
14
(I) the nature, circumstances, ex-
15
tent, and gravity of the violation; 
16
(II) with respect to the violator, 
17
the degree of culpability, any history 
18
of violations, the ability to pay, any 
19
effect on the ability to continue doing 
20
business, profits earned by the NDA 
21
or BLA holder (or, in the case of an 
22
agreement between two subsequent fil-
23
ers, the subsequent filer who gave the 
24
value described in subsection (a)(1)), 
25
23:50 Jan 28, 2021
H153
11 
•HR 153 IH
compensation received by the subse-
1
quent filer (or, in the case of an 
2
agreement between two subsequent fil-
3
ers, the subsequent filer who received 
4
the value described in subsection 
5
(a)(1)), and the amount of commerce 
6
affected; and 
7
(III) other matters that justice 
8
requires. 
9
(D) INJUNCTIONS AND OTHER EQUITABLE 
10
RELIEF.—In a civil action under subparagraph 
11
(A), the United States district courts are em-
12
powered to grant mandatory injunctions and 
13
such other and further equitable relief as they 
14
deem appropriate. 
15
(4) REMEDIES
IN
ADDITION.—Remedies pro-
16
vided in this subsection are in addition to, and not 
17
in lieu of, any other remedy provided by Federal 
18
law. 
19
(5) PRESERVATION OF AUTHORITY OF COMMIS-
20
SION.—Nothing in this section shall be construed to 
21
affect any authority of the Commission under any 
22
other provision of law. 
23
(e) FEDERAL TRADE COMMISSION RULEMAKING.— 
24
The Commission may, in its discretion, by rule promul-
25
23:50 Jan 28, 2021
H153
12 
•HR 153 IH
gated under section 553 of title 5, United States Code, 
1
exempt from this section certain agreements described in 
2
subsection (a) if the Commission finds such agreements 
3
to be in furtherance of market competition and for the 
4
benefit of consumers. 
5
(f) ANTITRUST LAWS.—Nothing in this section shall 
6
modify, impair, limit, or supersede the applicability of the 
7
antitrust laws as defined in subsection (a) of the first sec-
8
tion of the Clayton Act (15 U.S.C. 12(a)), and of section 
9
5 of the Federal Trade Commission Act (15 U.S.C. 45) 
10
to the extent that such section 5 applies to unfair methods 
11
of competition. Nothing in this section shall modify, im-
12
pair, limit, or supersede the right of a subsequent filer 
13
to assert claims or counterclaims against any person, 
14
under the antitrust laws or other laws relating to unfair 
15
competition. 
16
(g) DEFINITIONS.—In this section: 
17
(1) AGREEMENT
RESOLVING
OR
SETTLING
A 
18
COVERED
PATENT
INFRINGEMENT
CLAIM.—The 
19
term ‘‘agreement resolving or settling a covered pat-
20
ent infringement claim’’ means any agreement 
21
that— 
22
(A) resolves or settles a covered patent in-
23
fringement claim; or 
24
23:50 Jan 28, 2021
H153
13 
•HR 153 IH
(B) is contingent upon, provides for a con-
1
tingent condition for, or is otherwise related to 
2
the resolution or settlement of a covered patent 
3
infringement claim. 
4
(2) COMMISSION.—The term ‘‘Commission’’ 
5
means the Federal Trade Commission. 
6
(3) COVERED PATENT INFRINGEMENT CLAIM.— 
7
The term ‘‘covered patent infringement claim’’ 
8
means an allegation made by the NDA or BLA hold-
9
er to a subsequent filer (or, in the case of an agree-
10
ment between two subsequent filers, by one subse-
11
quent filer to another), whether or not included in 
12
a complaint filed with a court of law, that— 
13
(A) the submission of the application de-
14
scribed in subparagraph (A) or (B) of para-
15
graph (8), or the manufacture, use, offering for 
16
sale, sale, or importation into the United States 
17
of a covered product that is the subject of such 
18
an application— 
19
(i) in the case of an agreement be-
20
tween an NDA or BLA holder and a sub-
21
sequent filer, infringes any patent owned 
22
by, or exclusively licensed to, the NDA or 
23
BLA holder of the covered product; or 
24
23:50 Jan 28, 2021
H153
14 
•HR 153 IH
(ii) in the case of an agreement be-
1
tween two subsequent filers, infringes any 
2
patent owned by the subsequent filer; or 
3
(B) in the case of an agreement between 
4
an NDA or BLA holder and a subsequent filer, 
5
the covered product to be manufactured under 
6
such application uses a covered product as 
7
claimed in a published patent application. 
8
(4) COVERED
PRODUCT.—The term ‘‘covered 
9
product’’ means a drug (as defined in section 201(g) 
10
of the Federal Food, Drug, and Cosmetic Act (21 
11
U.S.C. 321(g))), including a biological product (as 
12
defined in section 351(i) of the Public Health Serv-
13
ice Act (42 U.S.C. 262(i))). 
14
(5) NDA OR BLA HOLDER.—The term ‘‘NDA 
15
or BLA holder’’ means— 
16
(A) the holder of— 
17
(i) an approved new drug application 
18
filed under section 505(b)(1) of the Fed-
19
eral Food, Drug, and Cosmetic Act (21 
20
U.S.C. 355(b)(1)) for a covered product; 
21
or 
22
(ii) a biologics license application filed 
23
under section 351(a) of the Public Health 
24
23:50 Jan 28, 2021
H153
15 
•HR 153 IH
Service Act (42 U.S.C. 262(a)) for a cov-
1
ered product; 
2
(B) a person owning or controlling enforce-
3
ment of the patent on— 
4
(i) the list published under section 
5
505(j)(7) of the Federal Food, Drug, and 
6
Cosmetic Act (21 U.S.C. 355(j)(7)) in con-
7
nection with the application described in 
8
subparagraph (A)(i); or 
9
(ii) any list published under section 
10
351 of the Public Health Service Act (42 
11
U.S.C. 262) comprised of patents associ-
12
ated with biologics license applications filed 
13
under section 351(a) of such Act (42 
14
U.S.C. 262(a)); or 
15
(C) the predecessors, subsidiaries, divi-
16
sions, groups, and affiliates controlled by, con-
17
trolling, or under common control with any en-
18
tity described in subparagraph (A) or (B) (such 
19
control to be presumed by direct or indirect 
20
share ownership of 50 percent or greater), as 
21
well as the licensees, licensors, successors, and 
22
assigns of each of the entities. 
23
23:50 Jan 28, 2021
H153
16 
•HR 153 IH
(6) PATENT.—The term ‘‘patent’’ means a pat-
1
ent issued by the United States Patent and Trade-
2
mark Office. 
3
(7) 
STATUTORY
EXCLUSIVITY.—The 
term 
4
‘‘statutory exclusivity’’ means those prohibitions on 
5
the submission or approval of drug applications 
6
under 
clauses 
(ii) 
through 
(iv) 
of 
section 
7
505(c)(3)(E) (5- and 3-year exclusivity), clauses (ii) 
8
through (iv) of section 505(j)(5)(F) (5-year and 3- 
9
year exclusivity), section 505(j)(5)(B)(iv) (180-day 
10
exclusivity), section 527 (orphan drug exclusivity), 
11
section 505A (pediatric exclusivity), or section 505E 
12
(qualified infectious disease product exclusivity) of 
13
the Federal Food, Drug, and Cosmetic Act (21 
14
U.S.C. 355(c)(3)(E), 355(j)(5)(B)(iv), 355(j)(5)(F), 
15
360cc, 355a, 355f), or prohibitions on the submis-
16
sion or licensing of biologics license applications 
17
under section 351(k)(6) (interchangeable biological 
18
product exclusivity) or section 351(k)(7) (biological 
19
product reference product exclusivity) of the Public 
20
Health Service Act (42 U.S.C. 262(k)(6), (7)). 
21
(8) SUBSEQUENT
FILER.—The term ‘‘subse-
22
quent filer’’ means— 
23
(A) in the case of a drug, a party that 
24
owns or controls an abbreviated new drug appli-
25
23:50 Jan 28, 2021
H153
17 
•HR 153 IH
cation submitted pursuant to section 505(j) of 
1
the Federal Food, Drug, and Cosmetic Act (21 
2
U.S.C. 355(j)) or a new drug application sub-
3
mitted pursuant to section 505(b)(2) of the 
4
Federal Food, Drug, and Cosmetic Act (21 
5
U.S.C. 355(b)(2)) and filed under section 
6
505(b)(1) of such Act (21 U.S.C. 355(b)(1)) or 
7
has the exclusive rights to distribute the cov-
8
ered product that is the subject of such applica-
9
tion; or 
10
(B) in the case of a biological product, a 
11
party that owns or controls an application filed 
12
with the Food and Drug Administration under 
13
section 351(k) of the Public Health Service Act 
14
(42 U.S.C. 262(k)) or has the exclusive rights 
15
to distribute the biological product that is the 
16
subject of such application. 
17
(h) EFFECTIVE DATE.—This section applies with re-
18
spect to agreements described in subsection (a) entered 
19
into on or after the date of the enactment of this Act. 
20
SEC. 3. NOTICE AND CERTIFICATION OF AGREEMENTS. 
21
(a) NOTICE OF ALL AGREEMENTS.—Section 1111(7) 
22
of the Medicare Prescription Drug, Improvement, and 
23
Modernization Act of 2003 (21 U.S.C. 355 note) is 
24
amended by inserting ‘‘or the owner of a patent for which 
25
23:50 Jan 28, 2021
H153
18 
•HR 153 IH
a claim of infringement could reasonably be asserted 
1
against any person for making, using, offering to sell, sell-
2
ing, or importing into the United States a biological prod-
3
uct that is the subject of a biosimilar biological product 
4
application’’ before the period at the end. 
5
(b) CERTIFICATION OF AGREEMENTS.—Section 1112 
6
of such Act (21 U.S.C. 355 note) is amended by adding 
7
at the end the following: 
8
‘‘(d) CERTIFICATION.—The Chief Executive Officer 
9
or the company official responsible for negotiating any 
10
agreement under subsection (a) or (b) that is required to 
11
be filed under subsection (c) shall, within 30 days of such 
12
filing, execute and file with the Assistant Attorney General 
13
and the Commission a certification as follows: ‘I declare 
14
that the following is true, correct, and complete to the best 
15
of my knowledge: The materials filed with the Federal 
16
Trade Commission and the Department of Justice under 
17
section 1112 of the Medicare Prescription Drug, Improve-
18
ment, and Modernization Act of 2003, with respect to the 
19
agreement referenced in this certification— 
20
‘‘ ‘(1) represent the complete, final, and exclu-
21
sive agreement between the parties; 
22
‘‘ ‘(2) include any ancillary agreements that are 
23
contingent upon, provide a contingent condition for, 
24
23:50 Jan 28, 2021
H153
19 
•HR 153 IH
were entered into within 30 days of, or are otherwise 
1
related to, the referenced agreement; and 
2
‘‘ ‘(3) include written descriptions of any oral 
3
agreements, representations, commitments, or prom-
4
ises between the parties that are responsive to sub-
5
section (a) or (b) of such section 1112 and have not 
6
been reduced to writing.’.’’. 
7
SEC. 4. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
8
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
9
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
10
is amended by inserting ‘‘section 2 of the Protecting Con-
11
sumer Access to Generic Drugs Act of 2021 or’’ after 
12
‘‘that the agreement has violated’’. 
13
SEC. 5. COMMISSION LITIGATION AUTHORITY. 
14
Section 16(a)(2) of the Federal Trade Commission 
15
Act (15 U.S.C. 56(a)(2)) is amended— 
16
(1) in subparagraph (D), by striking ‘‘or’’ after 
17
the semicolon; 
18
(2) in subparagraph (E), by inserting ‘‘or’’ 
19
after the semicolon; and 
20
(3) by inserting after subparagraph (E) the fol-
21
lowing: 
22
‘‘(F) under section 2(d)(3)(A) of the Pro-
23
tecting Consumer Access to Generic Drugs Act 
24
of 2021;’’. 
25
23:50 Jan 28, 2021
H153
20 
•HR 153 IH
SEC. 6. STATUTE OF LIMITATIONS. 
1
(a) IN GENERAL.—Except as provided in subsection 
2
(b), the Commission shall commence any administrative 
3
proceeding or civil action to enforce section 2 of this Act 
4
not later than 6 years after the date on which the parties 
5
to the agreement file the Notice of Agreement as provided 
6
by section 1112(c)(2) and (d) of the Medicare Prescription 
7
Drug, Improvement, and Modernization Act of 2003 (21 
8
U.S.C. 355 note). 
9
(b) CIVIL ACTION AFTER ISSUANCE OF CEASE AND 
10
DESIST ORDER.—If the Commission has issued a cease 
11
and desist order under section 5 of the Federal Trade 
12
Commission Act (15 U.S.C. 45) for violation of section 
13
2 of this Act and the proceeding for the issuance of such 
14
order was commenced within the period required by sub-
15
section (a) of this section, such subsection does not pro-
16
hibit the commencement, after such period, of a civil ac-
17
tion under section 2(d)(3)(A) against a party to such 
18
order or a civil action under subsection (l) of such section 
19
5 for violation of such order. 
20
Æ 
23:50 Jan 28, 2021
H153
